Quarterly report · Q3
8129.TEDINET S100Q4UF
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.06T | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥1.27T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥950.2bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥8.6bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥5.5bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥13.4bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.9bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥14.4bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥10.4bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥9.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.9bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥9.6bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥6.9bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥794.4bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥702.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥731.5bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥554.0bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥461.1bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥240.4bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥241.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥238.4bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥112.9bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥94.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥136.09 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.9 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥189.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥97.98 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥51.58 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥125.1 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥174.48 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥90.07 | 2021-04-01 → 2021-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 30.2% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.5% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥43.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥43.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥1.1bn |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥68.8bn |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥68.8bn |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥4m |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.7bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥7.4bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥5.8bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥715m |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.02T |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥983.6bn |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥36.4bn |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥6.8bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥4.9bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥3.8bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥449m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥1.10T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥1.06T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥43.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥9.7bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥43.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥43.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥1.4bn |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥68.9bn |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥68.9bn |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥5m |
| jpcrp040300-q3r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥2.3bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥6.7bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥1.4bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥5.3bn |
| jpcrp040300-q3r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥691m |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥913.8bn |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥876.8bn |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥37.0bn |
| jpcrp040300-q3r_E02608-000Medical Products Retailreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥3.6bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥4.2bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥3.1bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥1.0bn |
| jpcrp040300-q3r_E02608-000Other Related Businessreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥308m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-12-31 | ¥993.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-12-31 | ¥950.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥43.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-12-31 | ¥6.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 418
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes financial instruments quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes securities quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes derivatives quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |